Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 620 mln. 675 mln. 632 mln. | Omzet 2025 * | 811 mln. 883 mln. 827 mln. | Marktkapitalisatie | 6,09 mld. 6,63 mld. 6,21 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 138 mln. 130 mln. | Nettowinst (verlies) 2025 * | 160 mln. 174 mln. 163 mln. | EV/omzet 2024 * | 9,72 x |
Nettoliquiditeiten 2024 * | 64,89 mln. 70,69 mln. 66,18 mln. | Nettoschuld 2025 * | 74,85 mln. 81,53 mln. 76,33 mln. | EV/omzet 2025 * | 7,6 x |
K/w-verhouding 2024 * |
50,7
x | K/w-verhouding 2025 * |
38,4
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1,06% | Dividendrendement 2025 * |
1,15% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +4,21% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,16% | 42,86 mld. | |
+12,21% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,87% | 25,15 mld. | |
-23,76% | 18,63 mld. | |
+27,24% | 12,37 mld. | |
-3,77% | 11,92 mld. | |
+7,18% | 11,21 mld. |